Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

INTRODUCTION: Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data were immature. Here, we present the final OS, quality of life (QoL), and safety da...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Long, Lu, Shun, Yang, James Chih-Hsin, Zhou, Jianying, Seto, Takashi, Ahn, Myung-Ju, Su, Wu-Chou, Yamamoto, Noboru, Kim, Dong-Wan, Paolini, Jolanda, Usari, Tiziana, Iadeluca, Laura, Wilner, Keith D., Goto, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558051/
https://www.ncbi.nlm.nih.gov/pubmed/36247019
http://dx.doi.org/10.1016/j.jtocrr.2022.100406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558051/
https://www.ncbi.nlm.nih.gov/pubmed/36247019
http://dx.doi.org/10.1016/j.jtocrr.2022.100406

Ejemplares similares